These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 30445935)

  • 21. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
    Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
    Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
    Aapro M; Krendyukov A; Höbel N; Gascon P
    Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13034. PubMed ID: 30968997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
    Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
    BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
    Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
    J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.
    McBride A; Campbell K; Bikkina M; MacDonald K; Abraham I; Balu S
    J Med Econ; 2017 Oct; 20(10):1083-1093. PubMed ID: 28722494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Gascon P; Krendyukov A; Gattu S; Li Y; Harbeck N
    Ann Oncol; 2018 Jan; 29(1):244-249. PubMed ID: 29091995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
    Tesch H; Ulshöfer T; Vehling-Kaiser U; Ottillinger B; Bulenda D; Turner M
    Oncol Res Treat; 2015; 38(4):146-52. PubMed ID: 25877937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
    Kamioner D; Fruehauf S; Maloisel F; Cals L; Lepretre S; Berthou C
    BMC Cancer; 2013 Nov; 13():547. PubMed ID: 24237790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
    Cornes P; Gascon P; Vulto AG; Aapro M
    BioDrugs; 2020 Jun; 34(3):255-263. PubMed ID: 32232676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
    Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
    Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
    Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework.
    Wang W; Li E; Campbell K; McBride A; D'Amato S
    JCO Oncol Pract; 2021 Aug; 17(8):e1139-e1149. PubMed ID: 33961490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
    Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.
    Verpoort K; Möhler TM
    Ther Adv Med Oncol; 2012 Nov; 4(6):289-93. PubMed ID: 23118804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective.
    Trautman H; Szabo E; James E; Tang B
    J Manag Care Spec Pharm; 2019 Jan; 25(1):94-101. PubMed ID: 30084301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.
    Bokemeyer C; Gascón P; Aapro M; Ludwig H; Boccadoro M; Denhaerynck K; Gorray M; Krendyukov A; Abraham I; MacDonald K
    Support Care Cancer; 2017 Jun; 25(6):1819-1828. PubMed ID: 28111718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.